Search results for "HERA"

showing 10 items of 14928 documents

Is Danggui Safe to be Taken by Breast Cancer Patients?-A Skepticism Finally Answered by Comprehensive Preclinical Evidence.

2019

Angelica sinensis (AS, Danggui) has long been regarded to stimulate breast cancer growth; hence, the use of AS in breast cancer patients remains a major concern for both patients and practitioners. Since safety studies of herbs would be unethical to carry out in patients, the present study aimed to investigate the potential unsafe effects of AS in a systematic pre-clinical approach. Human breast cancer cells, breast orthotopic tumor-bearing mouse models, as well as primary breast cancer cells from patients’ tumors were used to evaluate the effect of AS hot water extract on the progression of breast tumors and/or growth of breast cancer cells. We showed that AS is not that stimulatory in bre…

0301 basic medicineOncologysafetymedicine.medical_specialtyprimary breast cancer cellsmedicine.drug_classXenotransplantationmedicine.medical_treatmentTraditional Chinese medicine03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinemedicinePharmacology (medical)skin and connective tissue diseasesOriginal ResearchPharmacologySafety studiesbusiness.industrylcsh:RM1-950Angelica sinensisChinese herbal medicinesmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyEstrogen030220 oncology & carcinogenesisCancer cellestrogenic herbsBreast cancer cellsPrimary breast cancerbusinessFrontiers in pharmacology
researchProduct

Impact of ultrasound extraction parameters on the antioxidant properties of Moringa oleifera leaves

2020

Recently, much interest has been focused on Moringa oleifera L., a highly versatile and sustainable plant. In addition to its nutritional properties, numerous bioactive compounds have been identified in M. oleifera leaves, for which healthy properties have been reported. In the present research, the impact of ultrasound-assisted extraction (UAE) on the recovery of the bioactive compounds from leaves was investigated. Firstly, an experimental design approach has been used to highlight the influence of some extraction parameters (solvent, solvent/dry leaves ratio, temperature, time) on phenol compound recovery and antioxidant activity. Solvent composition was the most influential factor

0301 basic medicineOptimizationPhysiologyClinical BiochemistryLiquid chromatographyBiochemistryMoringa03 medical and health scienceschemistry.chemical_compoundMoringa oleifera leaves0404 agricultural biotechnologyFlavonolsDry matterFood scienceGallic acidMolecular Biologychemistry.chemical_classification030109 nutrition & dieteticsLiquid chromatography Moringa oleifera leaves Optimization Phenol compounds UAEExtraction (chemistry)lcsh:RM1-95004 agricultural and veterinary sciencesCell Biology040401 food scienceSolventPhenol compoundslcsh:Therapeutics. PharmacologychemistryUAEKaempferolQuercetin
researchProduct

Optimization of Lead Placement in the Right Ventricle During Cardiac Resynchronization Therapy. A Simulation Study

2019

[EN] Patients suffering from heart failure and left bundle branch block show electrical ventricular dyssynchrony causing an abnormal blood pumping. Cardiac resynchronization therapy (CRT) is recommended for these patients. Patients with positive therapy response normally present QRS shortening and an increased left ventricle (LV) ejection fraction. However, around one third do not respond favorably. Therefore, optimal location of pacing leads, timing delays between leads and/or choosing related biomarkers is crucial to achieve the best possible degree of ventricular synchrony during CRT application. In this study, computational modeling is used to predict the optimal location and delay of p…

0301 basic medicineOptimizationcomputational modelingmedicine.medical_specialtyQRS durationPhysiologymedicine.medical_treatmentCardiac resynchronization therapycardiac resynchronization therapyheart failureHeart failureLBBB030204 cardiovascular system & hematologylcsh:PhysiologyTECNOLOGIA ELECTRONICA03 medical and health sciencesQRS complex0302 clinical medicinePhysiology (medical)Internal medicinemedicinecardiovascular diseasesOriginal ResearchCardiac resynchronization therapylcsh:QP1-981business.industryComputational modelingmedicine.disease030104 developmental biologymedicine.anatomical_structureVentricleHeart failureCardiologycardiovascular systemLead PlacementbusinessoptimizationFrontiers in Physiology
researchProduct

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

2019

The unprecedented clinical activity of checkpoint blockade in several types of cancers has formally demonstrated that anti-tumor immune responses are crucial in cancer therapy. Durable responses seen in patients treated with immune checkpoint inhibitors (ICI) show that they can trigger the establishment of long-lasting immunologic memory. This beneficial outcome is however achieved for a limited number of patients. In addition, late relapses are emerging suggesting the development of acquired resistances that compromise the anticancer efficacy of ICI. How can this be prevented through combination therapies? We here review the functions of immune checkpoints, the successes of ICI in treating…

0301 basic medicineOrganoplatinum CompoundsImmune checkpoint inhibitorsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorLeucovorinReviewLymphocyte ActivationchemotherapyimmunomodulationB7-H1 AntigenMice0302 clinical medicineAntineoplastic Agents ImmunologicalcheckpointT-Lymphocyte SubsetsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentImmunology and AllergyCTLA-4 AntigenMolecular Targeted TherapyClinical Trials as TopicLymphokinesDrug Synergism3. Good healthNeoplasm ProteinsFluorouracillcsh:Immunologic diseases. AllergyImmunologyCancer therapyT cells03 medical and health sciencesImmune systemmedicineAnimalsHumanscancerIn patientChemotherapybusiness.industryCancermedicine.diseaseIpilimumabBlockade030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer researchlcsh:RC581-607business030215 immunologyFrontiers in immunology
researchProduct

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague–Dawley Rats But Aflibercept Affects…

2019

Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents. These biologics, however, possess a distinct toxicity profile, and they may also exacerbate the adverse effects of traditional chemotherapeutics. In this study, we aimed to characterize the gastrointestinal and metabolic changes after a 2-week treatment period with aflibercept, an antiangiogenic VEGFR decoy, and with erlotinib, a tyrosine-kinase inhibitor. Male rats were treated either with aflibercept or erlotinib for 2 weeks. During the 2-week treatment period, the animals in …

0301 basic medicineOriginal articleCancer ResearchBevacizumabANTITUMOR-ACTIVITYmedicine.medical_treatmentBEVACIZUMAB3122 CancersAdipose tissuePharmacologylcsh:RC254-282TOXICITY03 medical and health sciences0302 clinical medicinemedicineOXIDATIVE STRESSCOMBINATIONAdverse effectAfliberceptChemotherapyIntestinal permeabilitybusiness.industryCHEMOTHERAPYmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMETASTATIC COLORECTAL-CANCER1ST-LINE TREATMENT030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSACIDToxicityErlotinibbusinessmedicine.drug
researchProduct

Circulating programmed death ligand-1 (cPD-L1) in non-smallcell lung cancer (NSCLC)

2018

// Silvia Vecchiarelli 1, * , Francesco Passiglia 2, * , Armida D’Incecco 3, * , Marianna Gallo 4 , Antonella De Luca 4 , Elisa Rossi 5 , Federica D’Inca 1 , Gabriele Minuti 1 , Lorenza Landi 1 , Chiara Bennati 1 , Michela Spreafico 1 , Manolo D’Arcangelo 1 , Valentina Mazza 1 , Nicola Normanno 4 and Federico Cappuzzo 1 1 Department of Oncology and Hematology, AUSL della Romagna, Ravenna, Italy 2 Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy 3 Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy 4 Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori "Fondazione G Pascale"-IRCCS, Naples, Italy 5 Fond…

0301 basic medicinePD-L1medicine.medical_specialtymedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Gastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineLung cancerSurvival analysisChemotherapyHematologybusiness.industrybiomarkersBiomarkermedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisCohortMann–Whitney U testImmunotherapybusinessNon-small-cell lung cancerResearch PaperProgrammed death
researchProduct

Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology

2020

Cancer immunotherapy utilizes the immune system to fight cancer and has already moved from the laboratory to clinical application. However, and despite excellent therapeutic outcomes in some hematological and solid cancers, the regular clinical use of cancer immunotherapies reveals major limitations. These include the lack of effective immune therapy options for some cancer types, unresponsiveness to treatment by many patients, evolving therapy resistance, the inaccessible and immunosuppressive nature of the tumor microenvironment (TME), and the risk of potentially life-threatening immune toxicities. Given the potential of nanotechnology to deliver, enhance, and fine-tune cancer immunothera…

0301 basic medicinePD-L1medicine.medical_treatmentimmune checkpoint inhibitorNanotechnologyReviewmacrophage03 medical and health sciencesMice0302 clinical medicineImmune systemDrug Delivery SystemsCancer immunotherapyPD-L1NeoplasmsPD-1MedicineAnimalsHumansNanotechnologytumor microenvironmentTreatment resistanceAdverse effecttoll like receptor (TLR)lcsh:QH301-705.5Tumor microenvironmentbiologybusiness.industryCancerGeneral Medicinemedicine.diseaseCombined Modality TherapyImmune therapy030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesissiRNAbiology.proteinCAR T cell therapymyeloid derived suppressor cells (MDSC)Immunotherapybusinessbi-specific antibody therapyCells
researchProduct

The Interplay between Genes and Psychosocial Home Environment on Physical Activity

2018

Introduction Genetic factors contribute to individual differences in physical activity, but it remains uncertain whether the magnitude of the genetic effects is modified by variations in home environments. We aimed to examine to what extent the psychosocial home environment in childhood and adolescence modifies the genetic influences on leisure time physical activity in young adulthood. Methods Participants were Finnish twins (N = 3305) who reported their leisure time physical activity at age 24 yr. The psychosocial home environment was assessed by twins at ages 12, 14, and 17 yr, as well as by their parents when the twins were age 12 yr. Gene–environment interaction modeling was performed …

0301 basic medicineParentsDevelopmental psychology0302 clinical medicineSurveys and QuestionnairesOrthopedics and Sports Medicine030212 general & internal medicineLongitudinal StudiesGene–environment interactionta315Childta515Finlandexerciseta3142twinsFamily Relationsgeneettiset tekijätPsychologyPsychosocialfyysinen aktiivisuusinorganic chemicalsAdolescentlongitudinalPhysical activityMEDLINEPhysical Therapy Sports Therapy and Rehabilitationpsykososiaaliset tekijätpitkittäistutkimushome atmospherecomplex mixturesArticle03 medical and health sciencesFamily relationsLeisure ActivitiesHumansExercisechildhoodnuoret aikuisetkaksostutkimusHome environmentExtramuralfungilapsuusequipment and suppliesTwin studykotiympäristökaksoset030104 developmental biologybacteriaGene-Environment Interactionadolescence
researchProduct

The Pharmacology of Visual Hallucinations in Synucleinopathies

2019

Visual hallucinations (VH) are commonly found in the course of synucleinopathies like Parkinson's disease and dementia with Lewy bodies. The incidence of VH in these conditions is so high that the absence of VH in the course of the disease should raise questions about the diagnosis. VH may take the form of early and simple phenomena or appear with late and complex presentations that include hallucinatory production and delusions. VH are an unmet treatment need. The review analyzes the past and recent hypotheses that are related to the underlying mechanisms of VH and then discusses their pharmacological modulation. Recent models for VH have been centered on the role played by the decoupling …

0301 basic medicineParkinson's diseaseParkinson's diseaseReviewPharmacologySerotonergicdefault mode network03 medical and health sciencesGlutamatergic0302 clinical medicineDopaminemedicinePharmacology (medical)Default mode networkPharmacologySynucleinopathiesDementia with Lewy bodiesbusiness.industrylcsh:RM1-950visual hallucinationmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisCholinergicSettore MED/26 - Neurologiasynucleinopathydementia with Lewy bodiesbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Long-Term in vivo Evaluation of Orthotypical and Heterotypical Bioengineered Human Corneas.

2020

Purpose: Human cornea substitutes generated by tissue engineering currently require limbal stem cells for the generation of orthotypical epithelial cell cultures. We recently reported that bioengineered corneas can be fabricated in vitro from a heterotypical source obtained from Wharton’s jelly in the human umbilical cord (HWJSC). Methods: Here, we generated a partial thickness cornea model based on plastic compression nanostructured fibrin-agarose biomaterials with cornea epithelial cells on top, as an orthotypical model (HOC), or with HWJSC, as a heterotypical model (HHC), and determined their potential in vivo usefulness by implantation in an animal model. Results: No major side effects …

0301 basic medicinePathology02 engineering and technology:Chemicals and Drugs::Carbohydrates::Polysaccharides::Sepharose [Medical Subject Headings]Umbilical cord:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]heterotypical human corneaTissue engineering:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Lagomorpha::Rabbits [Medical Subject Headings]Cornea:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Optical Imaging::Tomography Optical::Tomography Optical Coherence [Medical Subject Headings]:Organisms::Eukaryota::Animals [Medical Subject Headings]:Technology and Food and Beverages::Technology Industry and Agriculture::Manufactured Materials::Biomedical and Dental Materials::Biocompatible Materials [Medical Subject Headings]Slit lamp021001 nanoscience & nanotechnologymedicine.anatomical_structure:Anatomy::Sense Organs::Eye::Anterior Eye Segment::Cornea [Medical Subject Headings]tissue engineeringStem cell0210 nano-technologyBiotechnology:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Fibrin [Medical Subject Headings]medicine.medical_specialtyHistologyStromal celllcsh:BiotechnologyBiomedical EngineeringCélulas madre mesenquimatosasBioengineering:Anatomy::Embryonic Structures::Fetus::Umbilical Cord [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models Animal [Medical Subject Headings]03 medical and health sciencesIn vivolcsh:TP248.13-248.65medicine:Anatomy::Cells::Connective Tissue Cells::Stromal Cells::Mesenchymal Stromal Cells [Medical Subject Headings]:Technology and Food and Beverages::Technology Industry and Agriculture::Engineering::Bioengineering::Cell Engineering::Tissue Engineering [Medical Subject Headings]Wharton’s jelly stem cellsbioengineered corneabusiness.industryTissue engineringeye diseasesEpitheliumCórnea:Anatomy::Cells::Epithelial Cells [Medical Subject Headings]:Anatomy::Tissues::Connective Tissue::Wharton Jelly [Medical Subject Headings]030104 developmental biologyIngeniería de tejidossense organsbusinessartificial cornea
researchProduct